SCHEDULE: Invus Group Discloses 9.4% Stake in vTv Therapeutics

Raymond Debbane and affiliated entities, including Invus Public Equities, report a combined beneficial ownership of 9.4% in vTv Therapeutics Inc. Class A Common Stock.

Summary

• Invus Public Equities, L.P. and its affiliates, along with Avicenna Life Sci Master Fund LP and its affiliates, and Raymond Debbane, filed an Amendment No. 1 to Schedule 13G regarding their beneficial ownership in vTv Therapeutics Inc.
• As of September 30, 2025, Raymond Debbane, through his control of various entities, beneficially owns 393,098 shares of Class A Common Stock, representing 9.4% of the class.
• Invus Public Equities, L.P. beneficially owns 345,926 shares, representing 8.4% of the class.
• Avicenna Life Sci Master Fund LP beneficially owns 47,172 shares, representing 1.2% of the class.
• The reported ownership includes direct shares, pre-funded warrants (exercisable at $0.01 per share with no expiration date), and common warrants (exercisable at $22.71 per share or $22.70 per pre-funded warrant, expiring September 3, 2030).
• Percentage calculations are based on 3,938,018 shares outstanding as of September 30, 2025, plus 230,098 shares issuable upon warrant exercise, totaling 4,168,116 shares.
• The reporting persons certify that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer, other than activities solely in connection with a nomination under Rule 14a-11.

Sentiment

Score: 5

Explanation: A Schedule 13G is a factual disclosure of beneficial ownership and does not inherently convey positive or negative sentiment regarding the company's performance or prospects, beyond the general implication of institutional interest.

Positives

• Significant beneficial ownership by institutional investors and a prominent individual (Raymond Debbane) may signal confidence in vTv Therapeutics Inc.'s long-term prospects.
• The inclusion of warrants in the holdings suggests a potential long-term investment perspective from the reporting entities.

Negatives

• No specific negatives are directly discernible from this Schedule 13G filing, which is a disclosure of ownership rather than operational or financial performance.

Risks

• The filing itself does not detail company-specific risks. The certification states that the shares were not acquired for the purpose of changing or influencing control, which is a legal compliance statement rather than a business risk.

Future Outlook

NA

Industry Context

Schedule 13G filings are routine disclosures by institutional investors or individuals who acquire more than 5% of a company's voting stock, indicating a passive investment intent. This filing reveals a significant stake by Invus Group affiliates and Raymond Debbane in vTv Therapeutics, a biotechnology company. Such disclosures can be viewed positively by the market as they signal institutional interest and potential long-term commitment, which is often crucial in the capital-intensive and research-driven biotechnology sector.

Related Party Transactions

• The filing details a clear control structure among the reporting persons: Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P.; Invus Global Management, LLC is the managing member of Invus Public Equities Advisors, LLC; Siren, L.L.C. is the managing member of Invus Global Management, LLC.
• Similarly, Avicenna Life Sci Master GP LLC is the general partner of Avicenna Life Sci Master Fund LP; Ulys, L.L.C. is the managing member of Avicenna Life Sci Master GP LLC.
• Raymond Debbane is the managing member of both Siren, L.L.C. and Ulys, L.L.C., thereby establishing his ultimate control over all listed entities and their beneficial ownership in vTv Therapeutics Inc.

Stakeholder Impact

• Shareholders: Increased transparency regarding significant institutional ownership, potentially signaling confidence from sophisticated investors and contributing to market stability.
• Company Management: Awareness of a substantial shareholder group, which could influence future strategic decisions or engagement with major investors.

Key Dates

Keywords

vTv Therapeutics Inc., Class A Common Stock, Schedule 13G, beneficial ownership, Invus Public Equities, Avicenna Life Sci Master Fund, Raymond Debbane, institutional investor, warrants, biotechnology, pharmaceuticals